LSP Dementia Fund

The LSP Dementia Fund is a venture capital fund dedicated to investing in companies developing breakthrough drug therapies and medical technologies for neurodegenerative diseases, particularly dementia. The fund aims to address the significant global health challenge posed by dementia, which affects millions worldwide and is projected to triple by 2050. By supporting innovative solutions, the fund seeks to bring new treatments to patients and generate strong financial returns for its investors.

Managed by EQT Life Sciences, the fund has raised approximately EUR 260 million, surpassing its original target of EUR 100 million. The investment team is led by Professor Philip Scheltens, a renowned dementia researcher, and includes partners with expertise in medicine, science, business, and finance. The fund's strategy involves investing in 10 to 15 companies, with initial investments in NewAmsterdam Pharma, Muna Therapeutics, AviadoBio, Nobi, and QurAlis.

The LSP Dementia Fund's approach combines deep sector knowledge with a commitment to advancing dementia research and treatment. By focusing on early-stage and growth-stage companies, the fund aims to support the development of innovative therapies that can make a meaningful impact on patients' lives. Its geographical focus includes Europe and the United States, reflecting a broad commitment to addressing the global challenge of dementia.